Sponsors (8)
Introduced May 15, 2025 by Gary C. Peters · Last progress May 15, 2025
The bill strengthens U.S. drug‑supply resilience and military readiness by increasing transparency, risk assessments, and interagency coordination — but it does so at the cost of added taxpayer and administrative burdens, potential proprietary and national‑security risks from data disclosures, and possible higher drug prices or reduced market participation by manufacturers.
Patients with chronic conditions and hospitals will face fewer drug shortages because the bill creates a publicly maintained essential medicines list, requires federal risk assessments, and mandates supply‑chain mapping to prioritize and mitigate shortages.
The public, Congress, and health systems will get clearer, regular transparency on which drugs and active pharmaceutical ingredients are at risk through public reports and updates, improving oversight and accountability about foreign reliance.
Military personnel and DoD beneficiaries will gain better visibility into medicines that rely on specific foreign sources (including China), supporting military readiness and targeted mitigation of defense supply‑chain risks.
Taxpayers and federal budgets will face increased administrative and program costs because maintaining lists, doing risk assessments, mapping supply chains, and implementing analytics and cybersecurity requires additional HHS/DoD and agency resources.
Manufacturers and small businesses may withhold data, limit transparency, or exit markets because required disclosures of facility locations, production amounts, or supplier sourcing raise proprietary and competitiveness concerns, which could ultimately worsen supply availability for patients.
Sensitive supply‑chain and procurement details could be exposed (or targeted) if reporting and public releases are not carefully redacted and secured, creating national security and cybersecurity risks for government and health infrastructure.
Based on analysis of 7 sections of legislative text.
Requires HHS to maintain an Essential Medicines List, assess and map supply chains for those drugs, report vulnerabilities, and requires DoD to report China-sourced drug purchases.
Requires the Department of Health and Human Services to maintain and update an "Essential Medicines List" and to lead a government-wide effort to assess, map, and visualize U.S. supply chains for those drugs and their active pharmaceutical ingredients (APIs). It directs HHS to identify vulnerabilities (including reliance on high-risk foreign suppliers), use data analytics to predict shortages, coordinate with Defense and other agencies, and report findings to Congress and the public on a set schedule. Also requires the Department of Defense to report regularly on drugs it purchased that were manufactured in or contained key inputs sourced from the People’s Republic of China, allows interagency data sharing for these tasks (while preserving trade-secret protections), and mandates cybersecurity safeguards for exchanged information.